Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Grünenthal Group and Amura Therapeutics have entered into research deal focused on the areas of pain and inflammation.
Subscribe to our email newsletter
Pursuant to the agreement, the companies will work together to develop cathepsin inhibitors that play a vital role in pain and inflammation.
Grünenthal will support the development of small molecule drugs, developed by Amura, and is responsible to advance the research.
Grünenthal Innovation executive vice president and chief operating officer Dr. Klaus-Dieter Langner said, "Our expertise, strength and innovative power in developing therapies for patients suffering from pain and inflammatory diseases hopefully will help these patients in the future as these are still areas of unmet medical need."
According to the agreement, Grünenthal gains all the clinical development, manufacturing and commercialisation rights of new pharmaceutical products resulting from the deal.
Amura earned an undisclosed upfront payment and is eligible to receive further milestone payments.
Amura chairman Dr David Brown said, "This Agreement provides confirmation of the scientific and commercial validity of Amura’s novel AMcore platform and we look forward to a fruitful partnership with Grünenthal and developing new medicines in an area of unmet medical need."